Accumetrics’ VerifyNow System Receives Health Canada License for Clinical Use
SAN DIEGO--(BUSINESS WIRE)--Aug 8, 2012--Accumetrics, Inc., developer of the VerifyNow ® System, the first rapid and easy-to-use system for measuring platelet reactivity to multiple antiplatelet agents, announced today that the VerifyNow System has been licensed for clinical use by Health Canada. The VerifyNow System is now available to hospitals and clinical laboratories in Canada to measure platelet reactivity in patients on antiplatelet medications including aspirin and P2Y12 inhibitors (clopidogrel).
Additionally, Accumetrics has signed an agreement with Force 3 Medical, Inc. for distribution of the VerifyNow System in Canada. With the addition of Force 3 Medical to Accumetrics’ growing number of distribution partners, Accumetrics now has local representation in over 70 countries worldwide.
“Achieving a Health Canada license is another important milestone in our mission to provide patients and healthcare professionals the highest quality clinical evidence that allows for improved management of cardiovascular disease throughout the world,” said Timothy I. Still, President and CEO of Accumetrics, Inc. “With Force 3 Medical as our Canadian distribution partner, we are very confident that the VerifyNow offering will quickly achieve a strong presence in this important market.” “The VerifyNow System is being used in the PROACT (Prospective Randomized ON-X Valve Anticoagulation Clinical Trial) study, and the four Canadian contributing centers have been impressed with its usefulness in managing patients’ antiplatelet treatment strategies,” said Gilbert Pommepuy, President and CEO of Force 3 Medical, Inc. “We are very excited at the prospect of being able to expand the use of the VerifyNow System and making it a new standard of care.” About Accumetrics ( ) Accumetrics is committed to advancing medical understanding of platelet function and enhancing quality of care for patients receiving antiplatelet therapies by providing industry-leading and widely accessible diagnostic tests for rapid platelet function assessment.
Accumetrics’ VerifyNow System is the first rapid and easy-to-use platform to help physicians determine an individual’s response to multiple antiplatelet agents. Addressing every major antiplatelet drug, including FDA-cleared products for aspirin and P2Y12 inhibitors (e.g. clopidogrel), the VerifyNow System provides valuable information to help physicians make informed clinical decisions. The VerifyNow P2Y12 Test is a whole blood assay used to measure the level of platelet P2Y12 receptor blockade. Additionally, it is indicated outside the US and Canada for evaluating the risk for recurrent events in cardiovascular patients. The VerifyNow System is used by physicians in over 800 facilities in the United States and over 70 countries worldwide where antiplatelet medications are prescribed to reduce the occurrence of future thrombotic events such as heart attack and stroke. For more information about the Company and its products, visit www.accumetrics.com.
The Accumetrics logo and VerifyNow are registered trademarks of Accumetrics, Inc.
About Force 3 Medical, Inc. Force 3 Medical, Inc. is a Canadian company distributing medical devices and equipment designed for cardiovascular physicians. With 29 years of experience in successfully launching new technologies to the Canadian cardiovascular/interventional cardiology market, the company specializes in the distribution and launch of innovative medical technology.CONTACT: Jakob Jakobsen 310-309-1003 (Office) 310-409-5351 (Cell) firstname.lastname@example.org or Gilbert Pommepuy, ing.
Force 3 Medical, Inc.
1-800-665-2040 email@example.com or Timothy I. Still President and CEO Accumetrics 858-404-8260 firstname.lastname@example.org KEYWORD: UNITED STATES NORTH AMERICA CANADA CALIFORNIA INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY MEDICAL DEVICES OTHER HEALTH GENERAL HEALTH SOURCE: Accumetrics, Inc. Copyright Business Wire 2012 PUB: 08/08/2012 09:54 AM/DISC: 08/08/2012 09:54 AM http://www.businesswire.com/news/home/20120808005742/